Mounjaro, Wegovy and Ozempic: Key Differences to Discuss With a Clinician
A cautious comparison for UK readers who want to understand the names before speaking to a prescriber or comparing regulated services.
Mounjaro contains tirzepatide. Wegovy and Ozempic contain semaglutide, but their licensed uses differ.
Access, eligibility and provider checks can differ depending on medicine, service and clinical history.
The right option depends on clinical suitability, risk, access and prescriber judgement.
Why these names get confused
Mounjaro, Wegovy and Ozempic are often discussed together because they are injectable medicines connected with appetite, weight and metabolic health. However, they are not interchangeable brand names. They contain different active ingredients or have different licensed uses, and a prescriber should decide what is appropriate.
Mounjaro contains tirzepatide. Wegovy contains semaglutide and is licensed for weight management where criteria are met. Ozempic also contains semaglutide but is primarily a diabetes medicine, so it should not be treated as a simple weight-loss alternative in consumer comparisons.
What differs in practice
The practical differences are not only about active ingredient. The provider route, eligibility criteria, dose schedule, side-effect profile, supply availability and follow-up expectations can all differ. A person who is unsuitable for one medicine is not automatically suitable for another.
- Ask what the medicine is licensed for in your situation.
- Check whether your medical history changes suitability.
- Ask how side effects and dose review are handled.
- Check supply and delivery information before ordering.
- Do not switch medicines without clinical advice.
Why average results are not a personal prediction
Clinical trial results can describe averages across groups. They do not predict exactly what will happen to one person. Starting weight, dose, tolerance, eating pattern, activity, other conditions and medicine adherence can all affect outcomes. A responsible comparison should avoid promising that one medicine will produce a specific result for every user.
Useful official context: GOV.UK explains that UK GLP-1 medicines have different licensed uses for diabetes and weight management. NICE and NHS England publish guidance on NHS access and commissioning for specific medicines.
Provider questions to ask
If you are comparing private providers, ask how the service decides suitability, whether it asks about previous GLP-1 use, what evidence it may require, and how it handles people switching from another medicine. Provider support matters because medicine comparison is not only a price decision.
When to choose a comparison page instead
If you already know which medicine you are researching, a provider comparison page may be more useful than a broad medicine comparison. It can help you compare support, delivery, fees and verification signals for that specific route.
Bottom line
There is no single best injectable medicine for everyone. Use this guide to understand the names, then rely on a qualified prescriber and regulated provider checks for decisions about suitability.
Useful next checks
Use these pages to connect this guide with provider, safety and cost checks.
Recent News About How It Works & Effectiveness
This guide is regularly reviewed. Here's what's changed recently in the UK: